News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.

Repligen down 7% as Evercore initiates in-line [Seeking Alpha]

Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $155.00 price target on the stock.

A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices [Yahoo! Finance]

2/20/2025

07:30 am

RGEN

5.1%

BEAT

2/20/2025

07:30 am

RGEN

5.1%

BEAT

2/20/2025

07:30 am

RGEN

6.2%

BEAT

11/12/2024

07:30 am

RGEN

1.6%

BEAT

Form ARS REPLIGEN CORP For: Dec 31

Form DEFA14A REPLIGEN CORP

Form DEF 14A REPLIGEN CORP For: Apr 03

Form 4 REPLIGEN CORP For: Apr 01 Filed by: Bylund James

Form 4 REPLIGEN CORP For: Mar 13 Filed by: Bylund James

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}